[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-sexual-dysfunction-fsd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-sexual-dysfunction-fsd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,76,106,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640280","biofeedback-assisted-pelvic-floor-rehabilitation-for-radiation-induced-sexual-dysfunction-in-cervical-cancer-survivors-100640280",false,"NCT07597083","Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors","Efficacy of Biofeedback-Assisted Pelvic Floor Muscle Training on Pelvic Radiation-Induced Sexual Dysfunction and Pelvic Floor Dysfunction in Cervical Cancer Survivors : A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female participants aged 30-60 years.\n2. Histologically confirmed diagnosis of cervical cancer (any stage at diagnosis) and completion of primary treatment.\n3. Completion of pelvic radiotherapy (external beam radiotherapy and\u002For brachytherapy) ≥3 months prior to enrollment.\n4. Presence of radiation-induced sexual dysfunction, defined as a Female Sexual Function Index (FSFI) score ≤26.55.\n5. Self-reported sexual activity within the previous 6 months.\n6. Medically stable with no current oncologic indication for active treatment, confirmed by treating oncologist.\n7. Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Evidence of recurrent, persistent, or metastatic cervical cancer.\n2. Participation in pelvic floor muscle training or biofeedback-based rehabilitation within the previous 6 months.\n3. Presence of severe pelvic organ prolapse (stage III-IV).\n4. Active pelvic infection, pelvic inflammatory disease, or untreated vaginal infection.\n5. Ongoing significant vaginal bleeding of unknown or pathological origin.\n6. Untreated or active urinary tract infection at the time of enrollment.\n7. Neurological disorders affecting pelvic floor function (e.g., spinal cord injury, multiple sclerosis).\n8. Severe psychiatric illness or uncontrolled mental health disorder affecting participation.\n9. Cognitive impairment preventing understanding of instructions or adherence to protocol.\n10. Current pregnancy or planning pregnancy during the study period.\n11. Participation in another interventional clinical or rehabilitation trial within the last 3 months or during the study period.","FEMALE","30 Years","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to evaluate the efficacy of biofeedback-assisted pelvic floor muscle training on radiation-induced sexual dysfunction in cervical cancer survivors following pelvic radiotherapy. Participants will be randomly assigned to receive either biofeedback-assisted pelvic floor rehabilitation or supervised conventional pelvic floor muscle training without biofeedback for 8 weeks.",[27,28,29],"Cervical Cancer","Female Sexual Dysfunction (FSD)","Radiation Induced Pelvic Floor Muscle Dysfunction",[31,32,33],"Cervical cancer","sexual dysfunction","electromyographic biofeedback pelvic floor muscle training","RECRUITING","2026-05-18",{"date":37,"type":38},"2026-05-20","ACTUAL",{"date":40,"type":38},"2026-05-19",{"date":42,"type":21},"2027-03-31",{"name":44,"class":45},"Beni-Suef University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100639970","effects-of-extracorporeal-shockwave-therapy-versus-pulsed-electromagnetic-field-therapy-in-females-with-sexual-dysfunction-100639970","NCT07584174","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction.","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score \\\u003C26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.\n2. Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.\n3. Symptoms persisting for at least 3 months before enrollment.\n4. Ability to understand study procedures and provide written informed consent.\n5. Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study period.\n2. Pelvic surgery within the previous 6 months.\n3. Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.\n4. Neurological disorders affecting pelvic floor or sexual function.\n5. Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.\n6. Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.\n7. Severe psychiatric disorders or cognitive impairment limiting participation.\n8. Menopause or perimenopausal status.\n9. Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.\n10. Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.\n11. Contraindications to ESWT or PEMF including cardiac pacemakers or implanted electronic devices, coagulation disorders, anticoagulant therapy, epilepsy, or metal implants in the pelvic region.\n12. Current participation in another clinical trial or receipt of physiotherapy for sexual dysfunction within the previous 3 months.","20 Years","50 Years",{"count":57,"type":21},90,[24],"This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction. Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.",[28,61,62,63],"Pelvic Floor Muscle Training","Shock Wave","Pulsed Electromagnetic Therapy",[65,66,67,68],"extracorporeal shock wave therapy","pulsed electromagnetic filed therapy","pelvic floor muscles training","females sexual dysfunction","2026-05-14",{"date":35,"type":38},{"date":69,"type":38},{"date":73,"type":21},"2027-01-15",{"name":75,"class":45},"Benha University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100566158","phase-2-evaluation-of-the-efficacy-in-increasing-sexual-arousal-safety-and-tolerability-of-bz371a-in-women-with-sexual-arousal-disorder-100566158","NCT06651541","Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder","Phase 2 Parallel Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women With Sexual Arousal Disorder","Inclusion Criteria:\n\n* Women aged between 21 and 65 years;\n* Premenopausal or postmenopausal women may be included;\n* May or may not be using female sex hormones (estrogen with or without progesterone, or their derivatives);\n* Women who have previously had sexual experiences with orgasm, desire, and arousal, for a minimum period of two years;\n* FSD, defined according to DSM-IV diagnostic criteria, that is, the presence of a persistent or recurrent inability to achieve or maintain adequate physiological sexual arousal during sexual activity, meaning a reduction or absence of genital response (lubrication, clitoral swelling, or other genital responses such as genital pleasure sensations);\n* FSD causes significant personal distress and\u002For interpersonal difficulty;\n* FSFI questionnaire meeting criteria for female sexual dysfunction, i.e., \\\u003C26.5;\n* Stable relationship for more than 6 months, with a sexually active partner who is present (cannot be traveling, for example) during the treatment period;\n* Ability to read and understand the Informed Consent Form (ICF) and to complete the questionnaires.\n\nExclusion Criteria:\n\n* Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;\n* Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;\n* Serious relationship problems, defined as a CSI-16 score below 51.5, of non-sexual origin, and which, in the investigator's opinion, may influence sexual activities;\n* History of unresolved sexual trauma or abuse, that could interfere with participation or the results of the study;\n* Diagnosis of vaginismus, genitopelvic pain\u002Fpenetration disorder and\u002For sexual aversion disorder;\n* Uncontrolled diabetes at screening visit (HbA1C \\> 10%);\n* Prior spinal cord injury, with lower limb paralysis;\n* History of abdominal or pelvic surgery that may have damaged pelvic nerves, including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension;\n* Current testosterone use, or long-term testosterone use (such as chip) within the past 6 months;\n* Patients with severe current depression, characterized by the use or need for the use of psychotropic medications, including bupropion, lithium, or neuroleptics (patients using antidepressant medications such as selective serotonin reuptake inhibitors may participate);\n* Presence of genital lesions that impair analysis of local adverse effects on the genitalia;\n* Presence of diseases that cause excessive vaginal discharge, such as recurrent urinary tract infection, vaginal infection and pelvic inflammatory disease.\n* Abnormal Papanicolaou test within the past 3 years;\n* History of gynecological cancer (history of uterine dysplasia can be included, provided it has been properly treated for at least 6 months);\n* History of pelvic irradiation;\n* Use of topical medications in the genital region that may interfere with PSI assessment as well as their absorption or drug interaction, including vaginal estrogens, lubricants, spermicides, creams or gels, vaginal douches;\n* History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart disease (including history of angina and\u002For heart failure) and nephropathies;\n* Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®)\n* ECG findings that are clinically symptomatic, or that, in the Investigator's judgment, are considered significant and pose a risk to the research volunteer's participation;\n* Findings on laboratory tests that, in the Investigator's judgment, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;\n* TSH outside the normal range for age and\u002For participants with hypothyroidism who started thyroid hormone replacement less than 3 months ago, even if TSH is within normal limits;\n* BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except for situations such as \"white coat\" syndrome;\n* Severe hypertension, considered to be the use of three or more antihypertensive drugs;\n* Diseases that can cause clitoral priapism, such as sickle cell anemia, multiple myeloma or leukemia;\n* History of clitoral priapism;\n* Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in the stool;\n* Pregnant or lactating;\n* Current use of nitric oxide donors, guanylate cyclase stimulators (e.g. Riociguat), or 5- phosphodiesterase inhibitors (Sildenafil, Tadalafil, etc.);\n* Any disease or condition or physical finding that the Investigator considers significant and that increases the risk of the research participant's participation or may interfere with the results, including serious debilitating diseases, presence of cancer, serious mental illness, persistent abuse of medication;\n* Partners with significant erectile dysfunction, defined as the inability to maintain an erection to provide satisfactory sexual intercourse in most sexual encounters;\n* Having participated in the BZ371CLI601 study;\n* Known hypersensitivity to BZ371A or any of the components of the formulation;\n* Significant tobacco or alcohol abuse that, in the investigator's opinion, may impair the participant's sexual function (light or moderate use of tobacco or alcohol is permitted);\n* Less than 3 valid sexual encounters, defined as a \"yes\" answer to question 7 of the FSEP, or use of less than 3 doses of PSI in the run-in period.","21 Years","65 Years",{"count":86,"type":21},174,[88],"PHASE2","Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder",[91,28],"Female Sexual Arousal Disorder",[32,93,94],"Topical application","female","NOT_YET_RECRUITING","2025-11-14",{"date":98,"type":38},"2025-11-17",{"date":100,"type":21},"2026-07-01",{"date":102,"type":21},"2027-07-31",{"name":104,"class":105},"Biozeus Biopharmaceutical S.A.","INDUSTRY",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100598963","effect-of-respiratory-exercises-with-pelvic-floor-rehab-on-dyspareunia--autonomic-function-in-women-100598963","NCT07078318","Effect of Respiratory Exercises With Pelvic Floor Rehab on Dyspareunia & Autonomic Function in Women","The Effect of Respiratory Exercises Given in Addition to Pelvic Floor Rehabilitation on Dyspareunia and Autonomic Nervous System in Women With Musculoskeletal Dyspareunia","Dyspareunia","Inclusion Criteria:\n\nFemale participants aged between 18 and 45 years\n\nExperiencing dyspareunia of musculoskeletal origin for at least 6 months\n\nIn a stable sexual relationship and sexually active\n\nWilling and able to attend weekly treatment sessions for 8 weeks\n\nAble to provide informed consent\n\nNo pelvic surgery within the last 6 months\n\nNormal cognitive function and ability to follow instructions\n\nBaseline FSFI score indicating sexual dysfunction (e.g., ≤ 26.55)\n\nExclusion Criteria:\n\n* Presence of neurological, gynecological, or urological pathologies causing pelvic pain (e.g., endometriosis, pelvic inflammatory disease)\n\nPregnancy or postpartum period within the last 6 months\n\nDiagnosed psychiatric disorders (e.g., major depression, psychosis)\n\nUse of medications that affect autonomic nervous system function (e.g., beta-blockers, antidepressants)\n\nHistory of pelvic radiation, cancer, or pelvic trauma\n\nParticipation in other rehabilitation or psychotherapy programs during the study period\n\nInability to tolerate manual therapy or perform breathing exercises\n\nBMI \\> 35, which may interfere with ultrasonographic assessment\n\nNon-compliance risk, such as irregular attendance or language barriers","18 Years","45 Years",{"count":117,"type":21},45,[24],"Background and Aim:\n\nDyspareunia, or pain during sexual intercourse, is a common component of female sexual dysfunction and may have multifactorial origins, including musculoskeletal and autonomic factors. While pelvic floor rehabilitation is an established treatment approach for musculoskeletal dyspareunia, it may not sufficiently address the autonomic dysregulation commonly observed in chronic pain conditions. The aim of this study is to investigate the effects of adding diaphragmatic breathing exercises and diaphragm manual therapy to standard pelvic floor rehabilitation on pain severity, pelvic floor function, and autonomic nervous system regulation in women diagnosed with musculoskeletal-origin dyspareunia.\n\nMethods:\n\nThis randomized controlled clinical trial will be conducted between September 1, 2025, and December 1, 2025, at the Kurbaa Training and Consultation Center in Istanbul. A total of 45 participants aged 18-45 years who meet the inclusion criteria will be randomly assigned into three equal groups (n = 15):\n\nGroup I: Pelvic floor rehabilitation only\n\nGroup II: Pelvic floor rehabilitation + diaphragmatic breathing exercises\n\nGroup III: Pelvic floor rehabilitation + diaphragmatic breathing exercises + diaphragm manual therapy\n\nInterventions will be administered once per week for 8 weeks. Pre- and post-intervention assessments will include pain intensity (Visual Analog Scale), pelvic floor muscle function (ultrasonography), sexual function (Female Sexual Function Index), anxiety level (Beck Anxiety Inventory), and autonomic regulation (Heart Rate Variability using Elite HRV). Statistical analyses will be performed using SPSS with significance set at p \\\u003C 0.05.\n\nExpected Contribution:\n\nThis study is expected to contribute to the development of more comprehensive treatment protocols for dyspareunia by integrating physical and neurophysiological rehabilitation components. It may also provide evidence supporting the role of autonomic regulation in improving treatment outcomes for female sexual pain disorders.",[121,28,122],"Dyspareunia (Female Excluding Psychogenic)","Chronic Pelvic Pain",[112,124,125,126,127],"Pelvic Floor Rehab","Manual Therapy","Autonomic Regulation","Sexual Dysfunction","2025-07-13",{"date":130,"type":38},"2025-07-22",{"date":132,"type":21},"2025-09-01",{"date":134,"type":21},"2026-12-01",{"name":136,"class":45},"Sakarya Applied Sciences University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":144,"minAge":114,"maxAge":4,"enrollmentInfo":145,"targetDuration":146,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":46},"100583789","developing-a-clinical-practice-guideline-with-the-delphi-technique-for-evaluation-and-counseling-of-womens-sexual-health-100583789","NCT06880900","Developing a Clinical Practice Guideline With The Delphi Technique for Evaluation and Counseling of Women's Sexual Health","Inclusion Criteria:\n\n* Women with sexual dysfunction\n* Women without any sexual dysfunction\n* Health professionals who specialize in women's sexual health (physician, nurse\u002Fmidwife, psychologist, academic)\n* Women and health professionals who agree to participate in the study\n\nExclusion Criteria:\n\n* Men with sexual dysfunction\n* Men without any sexual dysfunction\n* Healthcare professionals (physician, nurse\u002Fmidwife, psychologist, academic) who do not have expertise in women's sexual health\n* Women who do not agree to participate in the study and health professionals",true,"ALL",{"count":57,"type":21},"4 Months","OBSERVATIONAL","Type of Research The research will be conducted prospectively and methodologically. The Delphi Technique, one of the qualitative research methods, will be used.\n\nLocation and Time of Research Data collection will take place between April 12, 2023, and June 12, 2024, at universities, non-governmental organizations (NGOs) operating in the field of sexual health, and hospitals located in Istanbul.\n\nPopulation and Sample of the Research A purposive sampling method will be used to select the participant group. Experts in sexual health working in universities, counseling centers, private and public hospitals, including nurses, physicians, psychologists, and academicians, as well as women with and without sexual dysfunction, will be included in the expert opinion team.\n\nThe ideal group size for the Delphi technique is reported to be 10-20 experts, with a minimum of 7, although this number may vary depending on the subject (Şahin, 2001). In this study, the target is to include 15 participants from each group, representing different fields, for a total of 90 participants.\n\nData Collection Before data collection, approval will be obtained from the Istanbul University-Cerrahpaşa Non-Interventional Clinical Research Ethics Committee and institutional permission from the Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, Gynecology and Obstetrics Polyclinic.\n\nThe research will consist of two main stages. In the first stage, a clinical practice guide for evaluating and counseling women's sexual health will be created using the Delphi technique. In the second stage, the guide will be made available, and feedback will be collected from practitioners and women regarding the guide.\n\nThe Delphi technique, which will be used in the first stage, is a valid and reliable data collection method that systematically gathers expert opinions. It also allows for consensus to be reached in cases where there are differences of opinion. One of the applications of the Delphi technique is the development of standards.\n\nClinical Practice Guidelines are developed worldwide using three different Delphi methods: de novo, translated guides, and adaptation. In this study, the de novo Delphi method is planned to be used. The de novo guideline development method is employed when no previous guideline exists for the field of study or when existing guidelines have lost their validity. This method includes steps such as selecting the topic, forming working groups, preparing a draft guideline based on evidence and recommendations, presenting the draft to expert opinion, publishing the final guideline, delivering it to the target audience, and re-evaluating and updating it.\n\nIn this study, instead of the classical Delphi technique, the E-Delphi technique will be used with the help of electronic communication tools. The research, which will be completed after three Delphi sessions, will involve contacting participants via email and telephone.\n\nIn the first stage, experts will be identified, and face-to-face meetings will be conducted with participants for introductions. The participants' views on evaluating women's sexual health and sexual health care standards will be collected over three separate sessions using the Delphi method.\n\nIn the second stage, the guide created will be provided to healthcare workers, and it will be expected that the sexual health of women with and without sexual dysfunction will be evaluated and counseled according to this guide. Feedback from practitioners and women regarding the guide will be collected during this stage. This pilot study will be applied to 10 healthcare workers and 10 women with and without sexual dysfunction. Participants' views on the guide will be evaluated using the \"Guide Satisfaction Survey (Appendix-4).\"\n\nData Collection Tool Separate data collection tools will be used for each of the three Delphi sessions.\n\nIn the first Delphi session, the \"I. Delphi Survey (Appendix-2)\" will include open-ended questions addressing the research problem and demographic information. Participants will also receive the \"Invitation Text (Appendix-1)\" and \"Informed Consent Form (Appendix-3)\" containing general information about the study process and the Delphi technique.\n\nIn the second Delphi session, suggestions from the I. Delphi Survey and a literature review conducted before the sessions will be used to create standard items. These items will be compiled into a Likert-type survey, called the \"II. Delphi Survey,\" designed to gather participants' opinions on the created items and determine their level of agreement. Participants will also be asked to add any new items, comments, or suggestions they may have.\n\nIn the third Delphi session, standard items resulting from the evaluation of data from the second Delphi session will be compiled into a Likert-type su",[28,150],"Sexuality and Reproductive Issues",[152,153,154,155],"female sexual dysfunction","Clinical Practice Guideline","Delphi Technique","Women's Sexual Health","2025-03-17",{"date":158,"type":38},"2025-03-18",{"date":160,"type":21},"2025-03-10",{"date":162,"type":21},"2025-06-03",{"name":164,"class":45},"Istanbul University - Cerrahpasa"]